White William B, Giles Thomas, Bakris George L, Neutel Joel M, Davidai Giora, Weber Michael A
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA.
Am Heart J. 2006 Jan;151(1):176-84. doi: 10.1016/j.ahj.2005.02.014.
Traditional clinical trials in hypertension measure the efficacy of antihypertensive drugs but may not fully assess their effectiveness in clinical practice. Community-based trials can provide this information but are limited because usually they are of open-label design and potentially subject to observer bias. Therefore, we used ambulatory blood pressure monitoring (ABPM), an automated and objective measure of blood pressure (BP) to overcome these shortcomings in a large community-based trial.
Patients with hypertension, either untreated or currently on treatment, were started on, or switched to, the angiotensin receptor blocker telmisartan 40 mg daily; after 2 weeks, if office BP remained > or = 140/85 mm Hg, the dose was increased to 80 mg, and if necessary, hydrochlorothiazide 12.5 mg was added after a further 4 weeks and continued for the final 4-week period. Baseline and treatment ABPM measurements were completed in 940 previously untreated patients and 675 previously treated patients.
The average reduction of the entire cohort was -10.7/-6.5 mm Hg (P < .0001; mean 24-hour BPs were reduced by 12/8 and 8/5 mm Hg in the untreated and previously treated patients, respectively). In contrast, the office BPs fell by an average of 23/12 and 17/10 mm Hg in previously untreated and treated patients. In 401 patients whose baseline 24-hour BP was > or = 130/85 mm Hg, the mean decrease in 24-hour BP was 16.8/11.4 mm Hg. Based on ABPM criteria, the BP was fully controlled (< 130/85 mm Hg) in 70% of patients, and based on office measurement criteria (< 140/90 mm Hg), in 79%.
Ambulatory BP monitoring demonstrated excellent control rates by telmisartan monotherapy or in combination with hydrochlorothiazide. Observer and measurement bias was substantial based on the changes from baseline by clinical measurements in contrast to ambulatory BP recordings. The successful use of this procedure in primary care research will create further opportunities to define the effectiveness of treatment in the environment in which it is customarily prescribed.
传统的高血压临床试验测量抗高血压药物的疗效,但可能无法充分评估其在临床实践中的有效性。基于社区的试验可以提供此类信息,但存在局限性,因为通常它们采用开放标签设计,可能存在观察者偏倚。因此,我们在一项大型基于社区的试验中使用动态血压监测(ABPM),这是一种自动且客观的血压测量方法,以克服这些缺点。
未接受治疗或目前正在接受治疗的高血压患者开始服用或换用每日40毫克的血管紧张素受体阻滞剂替米沙坦;2周后,如果诊室血压仍≥140/85毫米汞柱,则剂量增加至80毫克,如有必要,在再过4周后加用12.5毫克氢氯噻嗪,并持续最后4周。在940名先前未接受治疗的患者和675名先前接受治疗的患者中完成了基线和治疗期间的ABPM测量。
整个队列的平均血压降幅为-10.7/-6.5毫米汞柱(P<.0001;未接受治疗和先前接受治疗患者的平均24小时血压分别降低了12/8和8/5毫米汞柱)。相比之下,先前未接受治疗和接受治疗患者的诊室血压平均下降了23/12和17/10毫米汞柱。在401名基线24小时血压≥130/85毫米汞柱的患者中,24小时血压的平均降幅为16.8/11.4毫米汞柱。根据ABPM标准,70%的患者血压得到充分控制(<130/85毫米汞柱),根据诊室测量标准(<140/90毫米汞柱),这一比例为79%。
动态血压监测显示,替米沙坦单药治疗或与氢氯噻嗪联合使用时血压控制率良好。与动态血压记录相比,基于临床测量的基线变化表明观察者和测量偏倚很大。该方法在初级保健研究中的成功应用将为确定在常规处方环境中的治疗效果创造更多机会。